stockrowSolventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
Follow SOLV
Alert me
Solventum Corporation (SOLV) Return on assets
Solventum Corporation's return on assets over the twelve months to 30 September 2026 was 1.11%, down 9.7 percentage points from fiscal 2025 (10.8%). That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 10.8% | 7.45 |
| FY2024 | 3.37% | (15.94) |
| FY2023 | 19.3% | 19.31 |
| FY2022 | 0.00% | — |
Return on assets against peers
| Company | Return on assets |
|---|---|
| WST West Pharmaceutical Services, Inc. compare | 15.7% |
| ALGN Align Technology, Inc. compare | 7.71% |
| ATR AptarGroup, Inc. compare | 5.23% |
| COO The Cooper Companies, Inc. compare | 4.55% |
| AVTR Avantor, Inc. compare | 2.89% |
| SOLV Solventum Corporation | 1.11% |
| RGEN Repligen Corporation compare | −0.40% |
| BLCO Bausch + Lomb Corporation compare | −0.80% |
| BAX Baxter International Inc. compare | −3.57% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on SOLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement